Hans-Peter Torsten Ekre
Gründer bei NEXTCELL PHARMA AB
Profil
Hans-Peter Torsten Ekre is the founder of Dilafor AB, founded in 2003, and NextCell Pharma AB, founded in 2014.
At NextCell Pharma AB, he holds the title of Independent Director.
Dr. Ekre's current job(s) include being a Director at IMED AB, Managing Director at KCIF Fund Management AB, and Director at ProNoxis AB.
Dr. Ekre's former job(s) include being Chairman at HBV Theranostica AB and NovaSAID AB, Director at KDev Exploratory AB, Avaris AB, Cytoguide ApS, Bioneris AB, and Palette Life Sciences AB.
He was also the Director of Research & Development at Astra AB from 1991 to 2000, Manager of Research & Development at Pharmacia AB from 1976 to 1991, and Investment Manager at Karolinska Development AB (Private Equity) from 2006 to 2012.
Additionally, he held the position of Investment Manager at Karolinska Development AB from 2003 to 2012.
Aktive Positionen von Hans-Peter Torsten Ekre
Unternehmen | Position | Beginn |
---|---|---|
NEXTCELL PHARMA AB | Gründer | 19.03.2014 |
IMED AB
IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | Direktor/Vorstandsmitglied | 26.11.2009 |
ProNoxis AB
ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Direktor/Vorstandsmitglied | 28.12.2009 |
KCIF Fund Management AB | Vorstandsvorsitzender | 21.04.2011 |
Ehemalige bekannte Positionen von Hans-Peter Torsten Ekre
Unternehmen | Position | Ende |
---|---|---|
Cytoguide ApS
Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Direktor/Vorstandsmitglied | 20.05.2014 |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Private Equity Investor | 31.12.2012 |
Bioneris AB
Bioneris AB Pharmaceuticals: MajorHealth Technology Bioneris is an specialized biotech innovation company and plans to work together with an industrial partner to commercialize the alpha trinositol molecule family. Bioneris has conducted a broad experimental series of pre-clinical trials that have demonstrated the effectiveness of alpha trinositol as a uniquely effective anti-cachexic agent. Bioneris will continue to develop the alpha trinositol molecule family and plans to develop additional applications for the molecule family. The company is also constantly expanding its extensive patent portfolio. Bioneris owns the exclusive rights to a large molecule family with an extensive clinical safety record and a large patent portfolio of approved patents. These factors contribute to the commercial potential of alpha trinositol and its derivatives. A common short coming of current cancer therapies is their safety profile, and Bioneris views the clinical safety record of alpha trinositol as an important advantage in its therapeutic and commercial application. Bioneris has conducted extensive pre-clinical cancer studies with a leading UK cancer research center. These experimental series have provided essential insights into the application and use of alpha trinositol in the treatment of cancer cachexia. Importantly, alpha trinositol is understood to have a therapeutic effect also in other indications besides cancer, such as restenosis, inflammation and arthritis. Bioneris has also elucidated the mode of action of alpha trinositol. | Direktor/Vorstandsmitglied | 19.01.2012 |
KAROLINSKA DEVELOPMENT AB | Chief Investment Officer | 01.01.2012 |
Astra AB
Astra AB Pharmaceuticals: MajorHealth Technology Astra AB used to manufacture and market cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. The firm's products were Pulmicort, Xylocaine, Marcaine, EMLA and Naropin. It had operations in Scandinavia, Europe, North & South America, Australia, New Zealand, Africa and Asia. The company was headquartered in Södertälje, Sweden. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2000 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
KAROLINSKA DEVELOPMENT AB | Finance |
NEXTCELL PHARMA AB | Health Technology |
Private Unternehmen | 14 |
---|---|
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Finance |
IMED AB
IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | Retail Trade |
KDev Exploratory AB
KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Commercial Services |
Avaris AB
Avaris AB Miscellaneous Commercial ServicesCommercial Services Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities. | Commercial Services |
ProNoxis AB
ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Health Technology |
Cytoguide ApS
Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Health Technology |
NovaSAID AB
NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | Health Technology |
Bioneris AB
Bioneris AB Pharmaceuticals: MajorHealth Technology Bioneris is an specialized biotech innovation company and plans to work together with an industrial partner to commercialize the alpha trinositol molecule family. Bioneris has conducted a broad experimental series of pre-clinical trials that have demonstrated the effectiveness of alpha trinositol as a uniquely effective anti-cachexic agent. Bioneris will continue to develop the alpha trinositol molecule family and plans to develop additional applications for the molecule family. The company is also constantly expanding its extensive patent portfolio. Bioneris owns the exclusive rights to a large molecule family with an extensive clinical safety record and a large patent portfolio of approved patents. These factors contribute to the commercial potential of alpha trinositol and its derivatives. A common short coming of current cancer therapies is their safety profile, and Bioneris views the clinical safety record of alpha trinositol as an important advantage in its therapeutic and commercial application. Bioneris has conducted extensive pre-clinical cancer studies with a leading UK cancer research center. These experimental series have provided essential insights into the application and use of alpha trinositol in the treatment of cancer cachexia. Importantly, alpha trinositol is understood to have a therapeutic effect also in other indications besides cancer, such as restenosis, inflammation and arthritis. Bioneris has also elucidated the mode of action of alpha trinositol. | Health Technology |
HBV Theranostica AB
HBV Theranostica AB Pharmaceuticals: MajorHealth Technology HBV Theranostica AB provides pharmaceutical research services. The company has developed a pretreatment marker for determining which patients with chronic hepatitis B virus infection are responders to a treatment with interferon-alpha. The company is headquartered in Solna, Sweden. | Health Technology |
Palette Life Sciences AB
Palette Life Sciences AB Medical SpecialtiesHealth Technology Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden. | Health Technology |
KCIF Fund Management AB | |
Dilafor AB
Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Pharmacia AB | Health Technology |
Astra AB
Astra AB Pharmaceuticals: MajorHealth Technology Astra AB used to manufacture and market cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. The firm's products were Pulmicort, Xylocaine, Marcaine, EMLA and Naropin. It had operations in Scandinavia, Europe, North & South America, Australia, New Zealand, Africa and Asia. The company was headquartered in Södertälje, Sweden. | Health Technology |